| Literature DB >> 28814268 |
G Banos1,2,3, G Bramis3, S J Bush1, E L Clark1, M E B McCulloch1, J Smith1, G Schulze4, G Arsenos3, D A Hume1, A Psifidi5,6.
Abstract
BACKGROUND: Mastitis is the most prevalent disease in dairy sheep with major economic, hygienic and welfare implications. The disease persists in all dairy sheep production systems despite the implementation of improved management practises. Selective breeding for enhanced mastitis resistance may provide the means to further control the disease. In the present study, we investigated the genetic architecture of four mastitis traits in dairy sheep. Individual animal records for clinical mastitis occurrence and three mastitis indicator traits (milk somatic cell count, total viable bacterial count in milk and the California mastitis test) were collected monthly throughout lactation for 609 ewes of the Greek Chios breed. All animals were genotyped with a custom-made 960-single nucleotide polymorphism (SNP) DNA array based on markers located in quantitative trait loci (QTL) regions for mastitis resistance previously detected in three other distinct dairy sheep populations.Entities:
Keywords: California mastitis test; Chios sheep; Dairy sheep; Genomic association; Mastitis; Milk transcriptome; Sheep transcriptomic atlas; Somatic cell count; Total viable bacterial count; Transcription factor binding sites
Mesh:
Substances:
Year: 2017 PMID: 28814268 PMCID: PMC5559839 DOI: 10.1186/s12864-017-3982-1
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Smoothed fixed curves of the mastitis traits studied in Chios sheep by week of lactation. Curves for milk somatic cell count (SCC), California mastitis test (CMT), total viable bacterial count in milk (TVC) and clinical mastitis occurrence (CM) are presented
Heritability (h2) and repeatability (r) estimates for four mastitis traits studied in Chios sheep, by stage of lactation
| Trait | Parameter | Early lactation | Mid lactation | Late lactation | Overall lactation |
|---|---|---|---|---|---|
| SCC | h2 | 0.10 (0.05) | 0.09 (0.05) | 0.18 (0.05) | 0.11 (0.05) |
| r | 0.55 (0.03) | 0.54 (0.02) | 0.66 (0.02) | 0.58 (0.02) | |
| CMT | h2 | 0.12 (0.06) | 0.10 (0.05) | 0.17 (0.06) | 0.12 (0.06) |
| r | 0.60 (0.03) | 0.59 (0.02) | 0.68 (0.02) | 0.62 (0.02) | |
| TVC | h2 | 0.09 (0.05) | 0.08 (0.04) | 0.15 (0.05) | 0.09 (0.05) |
| r | 0.28 (0.04) | 0.27 (0.03) | 0.34 (0.04) | 0.33 (0.04) | |
| CM | h2 | NA | NA | NA | 0.18 (0.10) |
| r | NA | NA | NA | 0.35 (0.06) |
SCC log-transformed milk somatic cell count; CMT California mastitis test; TVC log-transformed total viable bacterial count in milk; CM clinical mastitis occurrence (0/1, analysed with a logit function); NA non-applicable; standard errors in parentheses
Estimates of genetic (above diagonal) and phenotypic (below diagonal) correlations between the mastitis traits studied in Chios sheep (overall lactation)
| SCC | CMT | TVC | CM | |
|---|---|---|---|---|
| SCC | 0.77 (0.11) | 0.56 (0.12) | 0.35 (0.16) | |
| CMT | 0.85 (0.02) | 0.21 (0.12) | 0.36 (0.17) | |
| TVC | 0.64 (0.02) | 0.65 (0.02) | 0.35 (0.17) | |
| CM | 0.35 (0.03) | 0.39 (0.03) | 0.33 (0.03) |
SCC log-transformed milk somatic cell counts; CMT California mastitis test; TVC log-transformed total viable bacterial count in milk; CM clinical mastitis occurrence (0/1); standard errors in parentheses
List of SNPs associated with clinical mastitis occurrence and three mastitis indicator traits in Chios sheep
| Trait | Lactation stage | SNP | aChr(position) | GAS | a | d | PVA | PVP | p | q |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ( | ( | ||||||||
| SCC | early (weeks 1–7) | oar3_OAR19_27,830,713 | 19(27830713) | 5.54E-04 | −0.39(0.00) | −0.09(0.42) | 0.36 | 0.04 | 0.62 | 0.38 |
| oar3_OAR19_27,397,476 | 19(27397476) | 7.74E-04 | −0.41(0.03) | 0.32(0.15) | 0.38 | 0.04 | 0.34 | 0.66 | ||
| OAR19_29193780 | 19(27558690) | 8.00E-04 | 0.46(0.00) | 0.30(0.04) | 0.4 | 0.04 | 0.75 | 0.25 | ||
| OAR19_29776311 | 19(28134366) | 1.28E-03 | 0.33(0.09) | 0.09(0.26) | 0.12 | 0.01 | 0.87 | 0.13 | ||
| late (weeks 18–23) |
|
|
|
|
|
|
|
|
| |
| oar3_OAR2_206,805,418 | 2(206805418) | 8.25E-05 | −0.27(0.00) | 0.45(0.13) | 0.07 | 0 | 0.99 | 0.01 | ||
| OAR2_219641896 | 2(207420807) | 1.65E-04 | −0.14(0.46) | 0.22(0.25) | 0.01 | 0 | 0.83 | 0.17 | ||
| OAR2_216496832 | 2(204569747) | 1.89E-04 | −0.22(0.04) | 0.01(0.91) | 0.11 | 0.01 | 0.38 | 0.62 | ||
| oar3_OAR2_208,711,940 | 2(208711940) | 6.73E-04 | 0.11(0.41) | −0.68(0.00) | 0.18 | 0 | 0.19 | 0.81 | ||
| oar3_OAR2_207,141,059 | 2(207141059) | 9.52E-04 | −0.14(0.00) | −0.84(0.00) | 0.14 | 0 | 0.96 | 0.04 | ||
| oar3_OAR2_205,201,880 | 2(205201880) | 1.44E-03 | −0.28(0.01) | 0.03(0.79) | 0.08 | 0.01 | 0.64 | 0.36 | ||
| oar3_OAR2_204,683,757 | 2(204683757) | 1.51E-03 | −0.20(0.04) | 0.09(0.42) | 0.04 | 0.01 | 0.49 | 0.51 | ||
|
|
|
|
|
|
|
|
|
| ||
| overall (weeks 1–23) | OAR16_38842323 | 16(35633299) | 1.69E-03 | −0.18(0.01) | 0.12(0.13) | 0.04 | 0 | 0.8 | 0.2 | |
| oar3_OAR19_27,830,713 | 19(27830713) | 1.45E-03 | −0.21(0.01) | 0.15(0.16) | 0.09 | 0.01 | 0.62 | 0.38 | ||
| CMT | early (weeks 1–7) | oar3_OAR19_27,397,476 | 19(27397476) | 3.67E-04 | −0.36(0.00) | 0.07(0.50) | 0.28 | 0.03 | 0.34 | 0.66 |
| oar3_OAR19_27,100,147 | 19(27100147) | 3.93E-04 | 0.57(0.06) | 0.33(0.31) | 0.39 | 0.05 | 0.85 | 0.15 | ||
| OAR19_29776311 | 19(28134366) | 4.78E-04 | 0.37(0.05) | 0.10(0.60) | 0.15 | 0.02 | 0.87 | 0.13 | ||
| OAR19_29193780 | 19(27558690) | 9.22E-04 | 0.42(0.00) | 0.21(0.12) | 0.31 | 0.04 | 0.75 | 0.25 | ||
| oar3_OAR19_27,723,161 | 19(27723161) | 1.18E-03 | 0.34(0.04) | 0.11(0.54) | 0.14 | 0.02 | 0.85 | 0.15 | ||
| mid (weeks 8–17) | oar3_OAR19_27,830,713 | 19(27830713) | 4.31E-04 | −0.20(0.01) | 0.09(0.35) | 0.11 | 0.01 | 0.62 | 0.38 | |
| OAR19_27896777 | 19(26442150) | 6.20E-04 | 0.61(0.01) | 0.15(0.56) | 0.19 | 0.04 | 0.91 | 0.09 | ||
| oar3_OAR19_27,264,253 | 19(27264253) | 9.35E-04 | 0.20(0.01) | −0.02(0.79) | 0.11 | 0.01 | 0.59 | 0.41 | ||
| late (weeks 18–23) | oar3_OAR2_206,805,418 | 2(206805418) | 9.71E-04 | −0.19(0.00) | 0.29(0.28) | 0.03 | 0 | 0.99 | 0.01 | |
| oar3_OAR3_130,101,204 | 3(130101204) | 1.18E-03 | 0.12(0.00) | 0.14(0.15) | 0.01 | 0 | 0.9 | 0.1 | ||
| OAR3_130,096,528.3SR | 3(130096528) | 1.32E-03 | 0.93(0.17) | 0.98(0.16) | 0.43 | 0.07 | 0.9 | 0.1 | ||
| oar3_OAR16_35,319,166 | 16(35319166) | 4.60E-04 | −0.22(0.12) | 0.26(0.16) | 0.04 | 0.01 | 0.81 | 0.19 | ||
| OAR16_37125504 | 16(34187287) | 1.21E-03 | −0.69(0.02) | −0.38(0.23) | 0.24 | 0.04 | 0.89 | 0.11 | ||
|
|
|
|
|
|
|
|
|
| ||
| oar3_OAR19_26,711,220 | 19(26711220) | 7.13E-04 | 0.08(0.00) | −0.03(0.74) | 0.01 | 0 | 0.93 | 0.07 | ||
| oar3_OAR19_27,830,713 | 19(27830713) | 1.16E-03 | −0.20(0.01) | 0.09(0.35) | 0.05 | 0.01 | 0.62 | 0.38 | ||
| OAR16_37125504 | 16(34187287) | 1.21E-03 | −0.69(0.02) | −0.38(0.23) | 0.24 | 0.04 | 0.89 | 0.11 | ||
| overall (weeks 1–23) | OAR16_37125504 | 16(34187287) | 1.08E-03 | −0.22(0.26) | 0.12(0.56) | 0.04 | 0.01 | 0.89 | 0.11 | |
| oar3_OAR19_27,100,147 | 19(27100147) | 1.09E-03 | 0.36(0.03) | 0.42(0.01) | 0.51 | 0.02 | 0.85 | 0.15 | ||
| oar3_OAR19_27,830,713 | 19(27830713) | 1.16E-03 | −0.18(0.00) | 0.09(0.21) | 0.07 | 0.01 | 0.62 | 0.38 | ||
| oar3_OAR19_27,830,713 | 19(27830713) | 8.81E-04 | −0.27(0.00) | 0.08(0.37) | 0.2 | 0.04 | 0.62 | 0.38 | ||
| TVC | early (weeks 1–7) |
|
|
|
|
|
|
|
|
|
| late (weeks 18–23) |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
| oar3_OAR2_206,805,418 | 2(206805418) | 4.11E-04 | −0.15(0.00) | 0.28(0.19) | 0.03 | 0 | 0.99 | 0.01 | ||
| OAR2_220844191 | 2(208597501) | 4.81E-04 | −0.10(0.22) | −0.16(0.10) | 0.05 | 0 | 0.69 | 0.31 | ||
| oar3_OAR2_206,036,682 | 2(206036682) | 1.24E-03 | −0.49(0.00) | −0.50(0.00) | 0.12 | 0.01 | 0.84 | 0.16 | ||
| overall (weeks 1–23) | OAR16_38842323 | 16(35633299) | 1.27E-03 | 0.05(0.00) | −0.01(0.84) | 0.06 | 0 | 0.8 | 0.2 | |
| OAR16_37125504 | 16(34187287) | 1.32E-03 | −0.30(0.01) | −0.13(0.29) | 0.15 | 0.01 | 0.89 | 0.11 | ||
| OAR19_27896777 | 19(26442150) | 9.83E-04 | 0.16(0.16) | −0.03(0.79) | 0.07 | 0 | 0.91 | 0.09 | ||
| CM |
|
|
|
|
|
|
|
|
| |
| early (weeks 1–7) | OAR16_37226202 | 16(34279856) | 4.16E-04 | 2.04(0.02) | −0.80(0.39) | 0.28 | 0.05 | 0.51 | 0.49 | |
| s74559 | 16(35801129) | 4.41E-04 | 3.50(0.53) | 2.81(0.61) | 0.33 | 0.02 | 0.58 | 0.42 | ||
| OAR16_37419505 | 16(34392335) | 1.21E-03 | −3.27(0.06) | 1.74(0.16) | 0.19 | 0.05 | 0.62 | 0.38 | ||
| OAR16_37539041 | 16(34550197) | 1.76E-03 | 1.60(0.01) | −1.17(0.13) | 0.26 | 0.05 | 0.39 | 0.61 | ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
| OAR19_29193780 | 19(27558690) | 4.95E-04 | 3.02(0.76) | 2.66(0.79) | 0.21 | 0.04 | 0.75 | 0.25 | ||
| oar3_OAR19_27,018,360 | 19(27018360) | 8.26E-04 | −1.11(0.05) | 0.95(0.12) | 0.26 | 0.05 | 0.46 | 0.54 | ||
|
|
|
|
|
|
|
|
|
| ||
| mid (weeks 8–17) |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| ||
| oar3_OAR5_96,077,046 | 5(96077046) | 1.08E-04 | 0.59(0.03) | 0.89(0.05) | 0.12 | 0.03 | 0.41 | 0.59 | ||
| oar3_OAR5_96,062,963 | 5(96062963) | 1.07E-03 | 0.44(0.07) | −0.22(0.14) | 0.12 | 0.02 | 0.43 | 0.57 | ||
| OAR16_37226202 | 16(34279856) | 1.26E-03 | 2.02(0.02) | 1.27(0.03) | 0.21 | 0.04 | 0.51 | 0.49 | ||
| OAR16_37539041 | 16(34550197) | 1.94E-03 | 1.60(0.01) | −1.17(0.13) | 0.26 | 0.05 | 0.39 | 0.61 | ||
| oar3_OAR19_26,565,985 | 19(26565985) | 5.65E-04 | −0.70(0.04) | 0.32(0.48) | 0.25 | 0.05 | 0.52 | 0.48 | ||
| oar3_OAR19_26808003 | 19(268,080,030 | 6.95E-04 | −0.58(0.05) | −0.07(0.97) | 0.14 | 0.02 | 0.74 | 0.26 | ||
| OAR19_29482474 | 19(27864985) | 1.30E-03 | −3.49(0.86) | −3.33(0.87) | 0.23 | 0.04 | 0.1 | 0.9 | ||
| late (weeks 18–23) | oar3_OAR5_96,114,753 | 5(96114753) | 1.81E-03 | 1.00(0.03) | 0.81(0.10) | 0.42 | 0.08 | 0.59 | 0.41 | |
| OAR5_104431404 | 5(95881956) | 2.89E-04 | 0.98(0.03) | 0.71(0.15) | 0.4 | 0.07 | 0.6 | 0.4 | ||
| OAR5_104389335_X | 5(95841910) | 9.99E-04 | 0.47(0.04) | 0.66(0.17) | 0.21 | 0.02 | 0.64 | 0.36 | ||
| oar3_OAR5_96,114,753 | 5(96114753) | 1.14E-03 | 0.62(0.01) | 0.32(0.25) | 0.24 | 0.04 | 0.59 | 0.41 | ||
| OAR19_29776311 | 19(28134366) | 1.08E-03 | 1.08(0.00) | 1.07(0.01) | 0.28 | 0.05 | 0.87 | 0.13 | ||
| oar3_OAR19_27,264,253 | 19(27264253) | 1.31E-03 | 1.00(0.03) | 0.23(0.64) | 0.42 | 0.08 | 0.59 | 0.41 | ||
| oar3_OAR19_28,110,151 | 19(28110151) | 1.53E-04 | 0.98(0.05) | 0.74(0.21) | 0.25 | 0.05 | 0.86 | 0.14 | ||
| oar3_OAR19_26,565,985 | 19(26565985) | 5.21E-04 | −0.42(0.06) | −0.06(0.82) | 0.1 | 0.02 | 0.52 | 0.48 | ||
| OAR19_29193780 | 19(27558690) | 1.35E-03 | 0.56(0.10) | 0.08(0.82) | 0.15 | 0.02 | 0.75 | 0.25 | ||
| overall (weeks 1–23) | oar3_OAR2_207,141,059 | 2(207141059) | 1.25E-03 | −0.24(0.00) | −1.95(0.01) | 0.1 | 0 | 0.96 | 0.04 | |
| oar3_OAR19_27,264,253 | 19(2726253) | 1.35E-03 | 0.88(0.00) | 0.11(0.71) | 0.36 | 0.07 | 0.59 | 0.41 |
SCC log-transformed milk somatic cell counts; CMT California mastitis Test; TVC total viable bacterial count in milk; CM occurrence of clinical mastitis
aChr(position) is based on the Oar v3.1 assembly; GAS P–value: P-value from genomic association study (genome-wide significant in bold, suggestive significance otherwise); a: additive allele substitution effect; d: dominance effect; PVA: proportion of the genetic variance explained by the SNP; PVP: proportion of the phenotypic variance explained by the SNP; p and q allelic frequencies. No significant associations were identified for TVC and SCC in mid lactation
Fig. 2Manhattan plots displaying the genomic association results of the mastitis traits studied in Chios sheep. Manhattan plots for milk somatic cell count (SCC) in early (a), late (b), and overall (c) lactation; for California mastitis test (CMT) in early (d), mid (e), late (f), and overall (g) lactation; for total viable bacterial count in milk (TVC) in early (h), late (i), and overall (j) lactation; for clinical mastitis occurrence (CM) in early (k), mid (l), late (m), and overall (n) lactation. Chromosome location is plotted against -log10(P). Red and blue lines, respectively, are thresholds for significance post-Bonferroni correction (P < 0.05) and for suggestive significance (accounting for one false positive per genome scan). No significant results were identified for TVC and SCC in mid lactation
Fig. 3Pathway and network analysis using the IPA software. a The most highly represented canonical pathways derived from genes located within the candidate regions for mastitis resistance in Chios sheep. The solid yellow line represents the significance threshold. The line joining squares represents the ratio of the genes represented within each pathway to the total number of genes in the pathway. b Two networks, both related to immunological disease, that illustrate the molecular interactions between the products of candidate genes selected from QTL regions for mastitis resistance in Chios sheep. Arrows with solid lines represent direct interactions and arrows with broken lines represent indirect interactions. Genes with white labels are those added to the IPA analysis because of their interaction with the target gene products
Fig. 4Differential expression of genes located in the candidate regions for mastitis resistance post treatment with LPS. Each column represents gene expression level in sheep bone marrow-derived macrophages 0, 2, 4, 7 and 24 h post treatment with LPS, respectively. Expression level is shown as (a) average TPM (transcripts per million) at the 5 different time points, and (b) as log2 fold change in expression at 2, 4, 7 and 24 h relative to expression at 0 h. Significance thresholds indicated as: P < 0.05*, P < 0.01** and P < 0.001***
Fig. 5Differential expression of genes located in the candidate regions for mastitis resistance across individuals with low, medium and high milk somatic cell count. Expression in milk somatic cells is shown as average TPM (transcripts per million) across all experimental replicates. Significance values were estimated using Tukey’s HSD post hoc test (P < 0.05*)
Selected candidate genes for mastitis resistance
| Gene Symbol | Gene name | Genomic location | Functions |
|---|---|---|---|
|
| Cytotoxic T-lymphocyte-associated protein 4 | 2: 204,777,523–204,784,522 | Inhibitory receptor acting as a major negative regulator of T-cell responses [ |
|
| Inducible T-cell co-stimulator | 2: 204,851,429–204,873,693 | Enhances all basic T-cell responses to a foreign antigen, namely proliferation, lymphokine secretion, the upregulation of molecules that mediate cell-cell interactions, and antibody secretion by B-cells [ |
|
| Isocitrate dehydrogenase 1 (NADP+), Soluble | 2:209,236,699–209,259,307 | Isocitrate dehydrogenases catalyse the oxidative decarboxylation of isocitrate to 2-oxoglutarate; IDH1 also indirectly participates in mitigating oxidative damage and in the regulation of glucose-induced insulin secretion [ |
|
| Suppressor of cytokine signalling 2 | 3:129,720,516–129,722,508 | A member of the suppressor of cytokine signalling (SOCS) family. SOCS family members are cytokine-inducible negative regulators of cytokine receptor signalling via the Janus kinase/signal transducer and activation of transcription pathway (the JAK/STAT pathway) [ |
|
| Plexin C1 | 3:130,271,380–130,424,374 | This gene encodes a member of the plexin family. Plexins are transmembrane receptors for semaphorins, a large family of proteins that regulate axon guidance, cell motility and migration, and the immune response [ |
|
| Chromodomain-helicase-DNA-binding protein 1 | 5:95,366,866–95,559,633 | This gene encodes a protein that has been implicated in the regulation of transcription [ |
|
| Complement component 6 | 16:33,267,815–33,338,265 | Constituents of the membrane attack complex, which plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells [ |
|
| Complement component 7 | 16:33,481,056–33,542,035 | |
|
| Complement component 9 | 16:35,014,734–35,075,088 | |
|
| Prostaglandin E receptor 4 | 16:33,690,480–33,707,155 | This receptor can activate T-cell factor signalling, mediate PGE2 induced expression of early growth response 1 (EGR1), regulate the level and stability of cyclooxygenase-2 mRNA, and lead to the phosphorylation of glycogen synthase kinase-3 [ |
|
| Dab, mitogen-responsive phosphoprotein, homolog 2 | 16:34,976,596–34,998,498 | Adapter protein that functions as a clathrin-associated sorting protein, required for the clathrin-mediated endocytosis of selected cargo proteins. Mediates the activation of transforming growth factor beta (TFG-beta)-stimulated c-Jun N-terminal kinases. May inhibit the canonical Wnt/beta-catenin signalling pathway. Plays a role in the colony stimulating factor 1 (CSF-1) signal transduction pathway. May also act as a tumour suppressor [ |
|
| FYN-binding protein | 16:35,170,143–35,269,324 | The protein encoded by this gene is an adapter for the FYN protein and lymphocyte cytosolic protein 2 signalling cascades in T-cells. The encoded protein is involved in platelet activation and controls the expression of interleukin-2; it may also play a role in linking T-cell signalling to remodelling of the actin cytoskeleton [ |
|
| Oncostatin M receptor | 16:35,426,282–35,474,718 | Oncostatin M is a secreted cytokine involved in homeostasis and in diseases involving chronic inflammation. It is a member of the gp130 family of cytokines that have pleiotropic functions in differentiation and cell proliferation, as well as being involved in hematopoietic, immunologic, and inflammatory networks [ |
|
| Caspase Recruitment Domain | 16:33,567,396–33,580,406 |
|